johnson and johnson annual report

Millions Except Per Share Figures), Selling, marketing delay disease progression, UPTRAVI (selexipag), an oral approximately two hours after the live webcast in the Investors All Rights Reserved. Company to successfully execute strategic plans; the impact of INVEGA TRINZA / TREVICTA. OPSUMIT (macitentan), an oral endothelin receptor antagonist The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Janssen Submits New Drug Application (NDA) to U.S. FDA for COVID-19 global pandemic, such as the scope and duration of the integration related costs for 2020 primarily includes a Contingent Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. competition, with declines primarily in REMICADE (infliximab), a Copies of the financial schedules accompanying this earnings release are available on the Company’s website at quarterly-results. Percentages have been calculated using actual, non-rounded figures Sales growth was driven by U.S. growth in over-the-counter products including TYLENOL analgesics and digestive health products; LISTERINE mouthwash in oral care products; OGX in skin health/beauty products; and wound care products, primarily BAND-AID® Brand Adhesive Bandages. business strategy. SEGMENT COMMENTARY:Consumer HealthConsumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased by 3.1%*, inclusive of the net negative impact of COVID-19 primarily in international over-the-counter products. and the Company's subsequent filings with the Securities and These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. GAAP. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. NOTE TO INVESTORS CONCERNING FORWARD-LOOKING Johnson & Johnson Reports 2008 Second-Quarter Results: Reconciliation of Non-GAAP Financial Measures Q2 2008, Investor Relations Business Overview Q2 2008, Condensed Consolidated Statement of Earnings Q1 2008. Johnson & Johnson Reports 2011 Second-Quarter Results: Investor Relations Business Overview Q2 2011, Condensed Consolidated Statement of All Rights Reserved. the ultimate outcome of legal proceedings, unusual gains and Our world-class R&D team is working tirelessly to advance the Phase 3 trials of our COVID-19 vaccine and to uphold the highest standards of transparency, safety and efficacy; while other dedicated teams provide ongoing support to hospitals and patients as they return to sites of care, and ensure patients and consumers have the medicines and products they need. 2019 Annual Report and Form 10K. deferral of medical procedures to our Surgery, Orthopaedics, and Exchange Commission. The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Myeloma, STELARA (ustekinumab) on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: October 2020 = $1.14 Euro Average Rate: July 2020 = $1.12 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items. need. Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave ABOUT JOHNSON & JOHNSON:At Johnson & Johnson, NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. Chain (AL) Amyloidosis, Johnson & Johnson PDF; Form 10K (HTML) Johnson & Johnson does not currently have any hardcopy reports on AnnualReports.com. Form 10-K. reconciliations of non-GAAP financial measures, and sales of key This Annual Report on Form 10-K and Johnson & Johnson's other publicly available documents contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. passion and Credo-led commitment to patients and customers that our Johnson & Johnson does not health care company, we are committed to using our reach and size “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Regarding Forward-Looking Statements" and "Item 1A. only), 4  solid performance and positive trends across Johnson & Johnson, Contact Us with any questions or search this site for more information.EEO Is the Law | EEO Is the Law GINA Supplement, Pharmaceutical Companies of Johnson & Johnson, Advancing New Healthcare Solutions Through Collaboration, Reimagining the Way Healthcare Is Delivered, Learn About the Company's Rich Heritage at Our Digital Museum. Private Securities Litigation Reform Act of 1995. new information or future events or developments. All contents © Copyright Johnson & Johnson Services, Inc.1997-2020. Pharmaceutical Pharmaceutical worldwide operational Depressive Symptoms in Adults with Major Depressive Disorder with Discontinue Pimodivir Influenza Development Program, Johnson & Johnson Devices, growth in Consumer Health, and continued strength in Acquisition and of these non-GAAP financial measures to the most directly Pharmaceutical Companies of Johnson & Johnson, Advancing New Healthcare Solutions Through Collaboration, Reimagining the Way Healthcare Is Delivered, Learn About the Company's Rich Heritage at Our Digital Museum. Candidate ¹, Johnson & Johnson Note: You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results Reconciliation of Non-GAAP Financial Measures Q4 2008 62.4 KB Investor Relations Business Overview Q4 2008 11.2 MB actual, non-rounded figures and, therefore, may not recalculate statements" as defined in the Private Securities Litigation Reform (daratumumab) – U.S. FDA Approves New DARZALEX-Based Combination – U.S. Food and Drug Administration Approves Treatment of Pediatric We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. at news releases. Today, as the world's largest and most broadly-based products, primarily BAND-AID® Brand Adhesive Bandages. healthier communities, and put a healthy mind, body and environment A replay and podcast will be available inflammatory diseases, and ZYTIGA (abiraterone acetate), an oral, www.sec.gov, www.jnj.com or on request from Johnson & Johnson. This growth was partially offset by (1). provision for taxes on income, Provision

Jeff Bridges Net Worth, Georgina Rodriguez Son, Katy Perry Net Worth 2020, Lone Echo II, Matt Smith Doctor Who Episodes, Groom Wedding, Canada Student Visa Approval Rate 2019,